Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines

Thyroid

Volumn 15, Issue 3, 2005, Pages 222-231

  Park, Jin Woo ^a,b   Zarnegar, Rasa ^a   Kanauchi, Hajime ^a   Wong, Mariwil G ^a   Hyun, William C ^c   Ginzinger, David G ^c   Lobo, Margaret ^a   Cotter, Philip ^d   Duh, Quan Yang ^e   Clark, Orlo H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Chungbuk National University College of Medicine   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHILDREN S HOSPITAL OAKLAND   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD97 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME 3P; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOSTASIS; DOWN REGULATION; DRUG EFFECT; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KARYOTYPE; NIS GENE; PPAR GAMMA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; TRANSCRIPTION REGULATION;

ADENOCARCINOMA, FOLLICULAR; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CHROMANS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 3; GENE REARRANGEMENT; HUMANS; KARYOTYPING; PLATELET AGGREGATION INHIBITORS; PPAR GAMMA; THIAZOLIDINEDIONES; THYROID NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 20144367845     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.222     Document Type: Article

References (50)

1. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP 1997 Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553-3562.
2. Mazzaferri EL 1999 An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421-427.
3. Landau D, Vini L, A'Hern R, Harmer C 2000 Thyroid cancer in children: The Royal Marsden Hospital experience. Eur J Cancer 36:214-220.
4. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318-4323.
5. Kebebew E, Wong MG, Siperstein AE, Duh Q-Y, Clark OH 1999 Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. J Clin Endocrinol Metab 84:2840-2847.
6. Van Herle AJ, Agatep ML, Padua DN 3d, Totanes TL, Canlapan DV, Van Herle HM, Juillard GJ 1990 Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells in vitro. J Clin Endocrinol Metab 71:755-763.
7. Schmutzler C, Köhrle J 2000 Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10:393-406.
8. Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG 2003 Retinoic acid for redifferentiation of thyroid cancer-Does it hold its promise? Eur J Endocrinol 148:395-402.
9. Davies GF, Khandelwal RL, Roesler WJ 1999 Troglitazone induces expression of PPARgamma in liver. Mol Cell Biol Res Commun 2:202-208.
10. Goretzki PE, Frilling A, Simon D, Roeher HD 1990 Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 118:48-63.
11. Zielke A, Tezelman S, Jossart GH, Wong M, Siperstein AE, Duh Q-Y, Clark OH 1998 Establishment of a highly differentiated thyroid cancer cell line of Hürthle cell origin. Thyroid 8:475-483.
12. Ambesi-Impiombato FS, Parks LA, Coon HG 1980 Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci USA 77:3455-3459.
13. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA 2000 PAX8-PPARgamma1 fusion in oncogene human thyroid carcinoma. Science 289:1357-1360.
14. Mitelman F (ed) ISCN 1995 An International System for Human Cytogenetic Nomenclature. Basel: Karger: Cytogenetics and Cell Genetics.
15. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, Clark OH 2002 Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132:984-990.
16. Issemann I, Green S 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650.
17. Corton JC, Anderson SP, Stauber A 2000 Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 40:491-518.
18. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C 1999 Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3:799-804.
19. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V 2002 Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952.
20. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R, Robinson BG 2003 Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88:354-357.
21. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318-2326.
22. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T 2001 Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86:2170-2177.
23. Martelli ML, Iuliano R, Le Pera I, Sama' I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M, Fusco A 2002 Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 87:4728-4735.
24. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H 2000 Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704-711.
25. Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP 1998 Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95:8806-8811.
26. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD 1999 Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1:330-339.
27. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP 1998 Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58:3344-3352.
28. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM 1998 Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046-1052.
29. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N, Kinoshita Y 2000 Expression of peroxisome proliferator-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 83:1394-1400.
30. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M 2000 Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270:400-405.
31. Berger J, Patel HV, Woods J, Hayes NS, Parent SA, Clemas J, Leibowitz MD, Elbrecht A, Rachubinski RA, Capone JP, Moller DE 2000 A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Mol Cell Endocrinol 162:57-67.
32. Nakashiro K, Begum NM, Uchida D, Kawamata H, Shintani S, Sato M, Hamakawa H 2003 Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. Oral Oncol 39:855-861.
33. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM 2000 Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 275:18527-18533.
34. Altiok S, Xu M, Spiegelman BM 1997 PPARgamma induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 11:1987-1998.
35. Pizzimenti S, Laurora S, Briatore F, Ferretti C, Dianzani MU, Barrera G 2002 Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. Free Radic Biol Med 32:233-245.
36. Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K, Kiyosawa K 2002 Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 24:1-7.
37. Eichler W, Hamann J, Aust G 1997 Expression characteristics of the human CD97 antigen. Tissue Antigens 50:429-438.
38. Aust G, Eichlere W, Laue S, Lehmann I, Heldin NE, Lotz O, Scherbaum WA, Dralle H, Hoang-Vu C 1997 CD97: A dedifferentiation marker in human thyroid carcinomas. Cancer Res 57:1798-1806.
39. Hoang-Vu C, Bull K, Schwarz I, Krause G, Schmutzler C, Aust G, Köhrle J, Dralle H 1999 Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab 84:1104-1109.
40. Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S 2002 Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol 145:129-135.
41. Riedel C, Levy O, Carrasco N 2001 Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 276:21458-21463.
42. Shimizu K, Shiratori K, Kobayashi M, Kawamata H 2004 Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. Pancreas 29:67-74.
43. Cho DH, Choi YJ, Jo SA, Jo I 2004 Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: Evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem 279:2499-2506.
44. Zhu X, Lin Y, Zhang J, Fu M, Mao Z, Chen YE 2003 Thiazolidinediones, a class of anti-diabetic drugs, inhibit Id2 expression through a PPARgamma-independent pathway in human aortic smooth muscle cells. Cell Mol Life Sci 60:212-218.
45. Weber SM, Scarim AL, Corbett JA 2004 PPARgamma is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic beta-cells. Am J Physiol Endocrinol Metab 286:E329-E336.
46. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA 2001 Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61:6213-6218.
47. Bae MA, Rhee H, Song BJ 2003 Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 139:67-75.
48. Okano H, Shiraki K, Inoue H, Yamanaka Y, Kawakita T, Saitou Y, Yamaguchi Y, Enokimura N, Yamamoto N, Sugimoto K, Murata K, Nakano T 2003 15-deoxy-delta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-kappaB activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. Lab Invest 83:1529-1539.
49. Baek SJ, Wilson LC, Hsi LC, Eling TE 2003 Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 278:5845-5853.
50. Nikitakis NG, Siavash H, Hebert C, Reynolds MA, Hamburger AW, Sauk JJ 2002 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br J Cancer 87:1396-1403.